# 💊 Project 2: AI-Powered Drug Discovery & Molecular Design

> **Real-World Inspiration:** AlphaFold 3 (Google DeepMind/Isomorphic Labs), Recursion Pharmaceuticals, Insilico Medicine, NVIDIA BioNeMo, Absci
>
> **Status:** Revolutionizing pharma — AlphaFold predicted 200M+ protein structures, Insilico's AI-discovered drug reached Phase II clinical trials in record 30 months, Recursion raised $1.5B for AI drug discovery

---

## 🌍 What's Happening in the Real World (2025-2026)

| Company | Product | Impact |
|---------|---------|--------|
| **DeepMind** | AlphaFold 3 | Predicts structure of ALL biomolecules — proteins, DNA, RNA, ligands. 200M+ structures open-sourced |
| **Isomorphic Labs** | AI Drug Design | DeepMind spinoff — using AlphaFold to design novel drugs. Partnership deals worth $3B+ with Eli Lilly and Novartis |
| **Insilico Medicine** | Pharma.AI | First AI-discovered drug to reach Phase II trials (ISM001-055 for IPF). Target → molecule in 18 months vs 4-5 years traditionally |
| **Recursion** | Recursion OS | Massive biological dataset (22 PB) + AI models. $1.5B raised. Acquired Exscientia for $688M |
| **NVIDIA** | BioNeMo | Cloud service for generative biology — protein design, molecular generation, docking simulation |
| **Absci** | Generative Drug Design | De novo antibody design using generative AI. Created functional antibodies from scratch |

---

## 🎯 Project Goal

Build an **AI Drug Discovery Pipeline** that can:
1. Identify disease targets from biomedical literature (NLP + RAG)
2. Predict protein structures and binding sites (deep learning)
3. Generate novel drug-like molecules (generative models)
4. Screen candidates for toxicity and efficacy (ADMET prediction)
5. Optimize lead compounds (reinforcement learning)
6. Design clinical trial protocols (LLM agents)
7. Monitor real-world evidence post-launch (NLP mining)

---

## 🧠 GenAI Skills & Tools Involved

```mermaid
mindmap
  root((💊 AI Drug<br/>Discovery))
    🧬 Molecular AI
      HuggingFace BioModels
      Keras GNN/VAE
      PEFT Fine-Tuning
      Transfer Learning
    📚 Biomedical Knowledge
      RAG PubMed Pipeline
      Advanced RAG
      LlamaIndex BioIndex
      Embeddings BioEmbeddings
      Vector Databases
    🤖 Agent Systems
      LangGraph Pipeline
      CrewAI Research Team
      AgenticAI Patterns
      Autogen Lab Agents
    🧠 LLM Backbone
      ClaudeAPI Analysis
      GeminiAPI Multimodal
      OpenAI GPT Scientific
      Prompt Engineering
    ⚡ Scale & Deploy
      Distributed Training
      Model Quantization
      Inference Engines
      AWS AI/ML SageMaker
    🛡️ Safety
      Guardrails Validation
      RLHF Drug Optimization
      NLP Literature Mining
      Few-Shot Classification
```

---

## 🏗️ System Architecture

```mermaid
graph TB
    subgraph Discovery["🔬 Target Discovery"]
        direction TB
        LIT["📄 Literature Mining<br/><i>PubMed, bioRxiv, patents</i>"]
        KG["🕸️ Knowledge Graph<br/><i>Disease-Gene-Drug</i>"]
        TARGET["🎯 Target ID<br/><i>Druggable targets</i>"]
    end

    subgraph Structure["🧬 Structure Prediction"]
        direction TB
        AF3["🔮 AlphaFold 3<br/><i>Protein structure</i>"]
        BIND["🔗 Binding Site<br/><i>Pocket detection</i>"]
        DOCK["⚓ Molecular Docking<br/><i>AutoDock / DiffDock</i>"]
    end

    subgraph Generation["🧪 Molecule Generation"]
        direction TB
        VAE["💫 MolVAE<br/><i>Variational Autoencoder</i>"]
        DIFF["🌊 MolDiffusion<br/><i>Diffusion models</i>"]
        RL["🎮 MolRL<br/><i>RL optimization</i>"]
        GNN["🕸️ GNN Filter<br/><i>Property prediction</i>"]
    end

    subgraph Screening["🔍 Virtual Screening"]
        direction TB
        ADMET["💊 ADMET Prediction<br/><i>Absorption, Distribution,<br/>Metabolism, Excretion, Toxicity</i>"]
        SYNTH["⚗️ Synthesizability<br/><i>Retrosynthesis AI</i>"]
        RANK["📊 Lead Ranking<br/><i>Multi-objective optimization</i>"]
    end

    subgraph Clinical["🏥 Clinical Intelligence"]
        direction TB
        TRIAL["📋 Trial Design Agent<br/><i>Protocol generation</i>"]
        PATIENT["👥 Patient Matching<br/><i>Eligibility screening</i>"]
        RWE["📈 Real-World Evidence<br/><i>Post-market surveillance</i>"]
    end

    subgraph Orchestration["🤖 AI Orchestration Layer"]
        direction LR
        AGENT["🧠 Research Director<br/><i>CrewAI orchestrator</i>"]
        RAG["📚 BioRAG<br/><i>Literature retrieval</i>"]
        LLM["💬 LLM Reasoning<br/><i>Claude + Gemini</i>"]
    end

    Discovery --> Structure
    Structure --> Generation
    Generation --> Screening
    Screening --> Clinical
    Orchestration --> Discovery
    Orchestration --> Structure
    Orchestration --> Generation
    Orchestration --> Screening
    Orchestration --> Clinical

    style Discovery fill:#1a1a2e,color:#fff,stroke:#E63946,stroke-width:2px
    style Structure fill:#0f3460,color:#fff,stroke:#00B4D8,stroke-width:2px
    style Generation fill:#533483,color:#fff,stroke:#FFB703,stroke-width:2px
    style Screening fill:#1a1a2e,color:#fff,stroke:#2ECC71,stroke-width:2px
    style Clinical fill:#0f3460,color:#fff,stroke:#E67E22,stroke-width:2px
    style Orchestration fill:#e94560,color:#fff,stroke:#fff,stroke-width:2px

    style LIT fill:#E74C3C,color:#fff,stroke:#E74C3C
    style KG fill:#9B59B6,color:#fff,stroke:#9B59B6
    style TARGET fill:#3498DB,color:#fff,stroke:#3498DB
    style AF3 fill:#00B4D8,color:#fff,stroke:#00B4D8
    style BIND fill:#2ECC71,color:#fff,stroke:#2ECC71
    style DOCK fill:#F39C12,color:#fff,stroke:#F39C12
    style VAE fill:#E67E22,color:#fff,stroke:#E67E22
    style DIFF fill:#8E44AD,color:#fff,stroke:#8E44AD
    style RL fill:#1ABC9C,color:#fff,stroke:#1ABC9C
    style GNN fill:#C0392B,color:#fff,stroke:#C0392B
    style ADMET fill:#27AE60,color:#fff,stroke:#27AE60
    style SYNTH fill:#3498DB,color:#fff,stroke:#3498DB
    style RANK fill:#E74C3C,color:#fff,stroke:#E74C3C
    style TRIAL fill:#FFB703,color:#000,stroke:#FFB703
    style PATIENT fill:#9B59B6,color:#fff,stroke:#9B59B6
    style RWE fill:#00B4D8,color:#fff,stroke:#00B4D8
    style AGENT fill:#E63946,color:#fff,stroke:#E63946
    style RAG fill:#2ECC71,color:#fff,stroke:#2ECC71
    style LLM fill:#F39C12,color:#fff,stroke:#F39C12
```

---

## 🔄 Drug Discovery Pipeline Flow

```mermaid
sequenceDiagram
    participant Scientist as 👨‍🔬 Scientist
    participant Director as 🤖 Research Director
    participant LitAgent as 📄 Literature Agent
    participant StructAgent as 🧬 Structure Agent
    participant MolAgent as 🧪 Molecule Agent
    participant ScreenAgent as 🔍 Screening Agent
    participant ClinAgent as 🏥 Clinical Agent

    Scientist->>Director: "Find a novel inhibitor for JAK2 kinase in myelofibrosis"

    rect rgb(26, 26, 46)
        Note over Director,LitAgent: 📖 Phase 1: Target Validation
        Director->>LitAgent: Search PubMed, patents, clinical trials
        LitAgent->>LitAgent: RAG over 35M+ PubMed abstracts
        LitAgent-->>Director: JAK2 V617F mutation confirmed, 3 binding sites, existing drug limitations
    end

    rect rgb(15, 52, 96)
        Note over Director,StructAgent: 🧬 Phase 2: Structure Analysis
        Director->>StructAgent: Predict JAK2 mutant structure
        StructAgent->>StructAgent: AlphaFold 3 prediction + binding pocket analysis
        StructAgent-->>Director: 3D structure + druggable pocket + key residues
    end

    rect rgb(83, 52, 131)
        Note over Director,MolAgent: 🧪 Phase 3: Molecule Generation
        Director->>MolAgent: Generate molecules for JAK2 pocket
        MolAgent->>MolAgent: MolDiffusion generates 10K candidates
        MolAgent->>MolAgent: RL optimizes for binding affinity + selectivity
        MolAgent-->>Director: Top 500 novel molecules (filtered by Lipinski)
    end

    rect rgb(233, 69, 96)
        Note over Director,ScreenAgent: 🔍 Phase 4: Virtual Screening
        Director->>ScreenAgent: Screen 500 candidates
        ScreenAgent->>ScreenAgent: ADMET prediction + docking + synthesizability
        ScreenAgent-->>Director: Top 10 leads ranked by multi-objective score
    end

    rect rgb(26, 26, 46)
        Note over Director,ClinAgent: 🏥 Phase 5: Clinical Planning
        Director->>ClinAgent: Design Phase I trial for top 3 leads
        ClinAgent->>ClinAgent: Protocol generation + patient matching + timeline
        ClinAgent-->>Director: Trial protocol + 50 eligible patients + 18-month timeline
    end

    Director-->>Scientist: Complete drug discovery report with 3 lead candidates
```

---

## 🧬 Molecular Generation Architecture

```mermaid
graph TB
    subgraph Encoder["🔬 Molecular Encoder"]
        SMILES["📝 SMILES String<br/><i>CC(=O)Oc1ccccc1</i>"]
        GRAPH["🕸️ Molecular Graph<br/><i>Atoms + bonds</i>"]
        FP["🔢 Fingerprints<br/><i>Morgan, ECFP4</i>"]
        EMB["🧮 Mol Embedding<br/><i>512-dim latent</i>"]
    end

    subgraph Generator["🧪 Generative Models"]
        direction TB
        TVAE["💫 Transformer VAE<br/><i>SMILES generation</i>"]
        GDIFF["🌊 Graph Diffusion<br/><i>3D molecule diffs</i>"]
        FLOW["🔄 Flow Matching<br/><i>Continuous generation</i>"]
    end

    subgraph Optimizer["🎮 RL Optimization"]
        direction TB
        REWARD["🏆 Reward Model<br/><i>Binding + ADMET + Novelty</i>"]
        PPO["📈 PPO Training<br/><i>Policy gradient</i>"]
        FILTER["🔍 Constraint Filter<br/><i>Drug-likeness rules</i>"]
    end

    subgraph Output["💊 Drug Candidates"]
        NOVEL["✨ Novel Molecules"]
        PROP["📊 Predicted Properties"]
        SYNTH2["⚗️ Synthesis Routes"]
    end

    SMILES --> EMB
    GRAPH --> EMB
    FP --> EMB
    EMB --> Generator
    Generator --> Optimizer
    REWARD --> PPO
    PPO --> FILTER
    Optimizer --> Output

    style Encoder fill:#1a1a2e,color:#fff,stroke:#00B4D8,stroke-width:2px
    style Generator fill:#533483,color:#fff,stroke:#FFB703,stroke-width:2px
    style Optimizer fill:#0f3460,color:#fff,stroke:#2ECC71,stroke-width:2px
    style Output fill:#e94560,color:#fff,stroke:#fff,stroke-width:2px

    style SMILES fill:#3498DB,color:#fff,stroke:#3498DB
    style GRAPH fill:#2ECC71,color:#fff,stroke:#2ECC71
    style FP fill:#E67E22,color:#fff,stroke:#E67E22
    style EMB fill:#9B59B6,color:#fff,stroke:#9B59B6
    style TVAE fill:#E74C3C,color:#fff,stroke:#E74C3C
    style GDIFF fill:#1ABC9C,color:#fff,stroke:#1ABC9C
    style FLOW fill:#F39C12,color:#fff,stroke:#F39C12
    style REWARD fill:#27AE60,color:#fff,stroke:#27AE60
    style PPO fill:#8E44AD,color:#fff,stroke:#8E44AD
    style FILTER fill:#C0392B,color:#fff,stroke:#C0392B
    style NOVEL fill:#00B4D8,color:#fff,stroke:#00B4D8
    style PROP fill:#FFB703,color:#000,stroke:#FFB703
    style SYNTH2 fill:#E63946,color:#fff,stroke:#E63946
```

---

## 🛠️ Tech Stack Mapping

| Component | Technology | GenAI Skill Used |
|-----------|-----------|-----------------|
| **Literature Mining** | PubMed RAG + BioLinkBERT | `NLP`, `RAG`, `AdvancedRAG`, `Embeddings` |
| **Knowledge Graph** | Neo4j + BioGPT | `LangChain`, `Vector-Databases` |
| **Protein Structure** | AlphaFold 3 + ESMFold | `Keras`, `DistributedTraining`, `TransferLearning` |
| **Molecule Generation** | MolVAE, DiffSBDD | `HuggingFace`, `PEFT-FineTuning` |
| **RL Optimization** | PPO on molecular properties | `RLHF` |
| **ADMET Prediction** | GNN + molecular fingerprints | `Keras`, `TransferLearning` |
| **Research Agents** | CrewAI scientist team | `CrewAI`, `AgenticAI`, `Autogen` |
| **Agent Workflow** | LangGraph discovery pipeline | `LangGraph`, `LangChain` |
| **Scientific Reasoning** | Claude Opus 4 + Gemini Pro | `ClaudeAPI`, `GeminiAPI`, `PromptEngineering` |
| **Classification** | Few-shot drug class prediction | `FewShotZeroShot`, `OpenAI-GPT` |
| **Safety Validation** | Guardrails for toxicity alerts | `Guardrails` |
| **Model Serving** | TensorRT for docking inference | `InferenceEngines`, `ModelQuantization` |
| **Cloud Training** | SageMaker distributed | `AWS-AI-ML`, `DistributedTraining` |
| **BioMedical Index** | LlamaIndex + PubMed | `LlamaIndex` |

---

## 📊 Implementation Phases

```mermaid
gantt
    title 💊 AI Drug Discovery — Implementation Roadmap
    dateFormat YYYY-MM-DD
    axisFormat %b %d

    section Phase 1 — BioRAG
        PubMed indexing (35M abstracts)           :p1a, 2026-03-03, 10d
        BioMedical embeddings (BioLinkBERT)       :p1b, 2026-03-03, 7d
        Disease-Gene knowledge graph              :p1c, 2026-03-10, 10d
        Literature agent (RAG + Claude)           :p1d, 2026-03-20, 7d

    section Phase 2 — Structure
        AlphaFold 3 integration                   :p2a, 2026-03-27, 10d
        Binding site detection                    :p2b, 2026-04-06, 7d
        Molecular docking pipeline                :p2c, 2026-04-13, 7d

    section Phase 3 — Generative
        MolVAE training (ZINC dataset)            :p3a, 2026-04-20, 14d
        Graph diffusion model                     :p3b, 2026-05-04, 14d
        RL optimization loop                      :p3c, 2026-05-18, 10d

    section Phase 4 — Screening
        ADMET prediction models                   :p4a, 2026-05-28, 10d
        Retrosynthesis planning                   :p4b, 2026-06-07, 7d
        Multi-objective ranking                   :p4c, 2026-06-14, 7d

    section Phase 5 — Clinical AI
        Trial protocol generator                  :p5a, 2026-06-21, 10d
        Patient matching system                   :p5b, 2026-07-01, 10d
        End-to-end pipeline integration           :p5c, 2026-07-11, 14d
```

---

## 🎯 Key Metrics

| Metric | Target | Benchmark |
|--------|--------|-----------|
| Target identification speed | < 2 weeks | Traditional: 1-2 years |
| Novel molecules generated per run | 10,000+ | Traditional screening: 1M (but random) |
| ADMET prediction accuracy | > 85% | Industry average: ~75% |
| Hit rate (active compounds) | > 15% | Traditional HTS: ~0.1% |
| Time to lead compound | < 6 months | Traditional: 2-3 years |
| Cost per discovery campaign | < $500K | Traditional: $5-10M+ |
